Boehringer Ingelheim and Eli Lilly's Jardiance gets big lift from heart failure indications

It’s been more than a year since Boehringer Ingelheim and Eli Lilly’s Jardiance became the first drug to score approvals for the two major types of heart failure (HF), opening a huge patient population and the potential for a sales bump.

So, how’s it going so far? On Wednesday, when BI reported its full-year 2022 sales figures, the company showed more evidence of the momentum the HF indications have brought. Jardiance generated 5.8 billion euros ($6.3 billion) of sales in 2022, good for a 39% increase from 2021.